A detailed history of Virtus ETF Advisers LLC transactions in Immatics N.V. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 7,115 shares of IMTX stock, worth $51,085. This represents 0.04% of its overall portfolio holdings.

Number of Shares
7,115
Previous 6,990 1.79%
Holding current value
$51,085
Previous $81,000 -0.0%
% of portfolio
0.04%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.93 - $12.92 $1,366 - $1,615
125 Added 1.79%
7,115 $81,000
Q2 2024

Aug 14, 2024

SELL
$9.78 - $13.49 $18,063 - $24,916
-1,847 Reduced 20.9%
6,990 $81,000
Q1 2024

May 15, 2024

SELL
$10.23 - $12.94 $6,240 - $7,893
-610 Reduced 6.46%
8,837 $92,000
Q4 2023

Feb 15, 2024

BUY
$7.36 - $10.89 $8,714 - $12,893
1,184 Added 14.33%
9,447 $99,000
Q3 2023

Nov 07, 2023

SELL
$11.01 - $12.62 $9,083 - $10,411
-825 Reduced 9.08%
8,263 $95,000
Q2 2023

Aug 14, 2023

SELL
$5.92 - $12.72 $8,181 - $17,579
-1,382 Reduced 13.2%
9,088 $104,000
Q1 2023

May 15, 2023

SELL
$6.74 - $9.44 $27,162 - $38,043
-4,030 Reduced 27.79%
10,470 $72,000
Q4 2022

Feb 14, 2023

BUY
$8.05 - $11.58 $116,725 - $167,910
14,500 New
14,500 $126,000
Q4 2021

Feb 14, 2022

SELL
$10.81 - $14.38 $188,504 - $250,758
-17,438 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$11.58 - $15.46 $10,560 - $14,099
-912 Reduced 4.97%
17,438 $227,000
Q2 2021

Aug 10, 2021

SELL
$10.43 - $12.81 $132,544 - $162,789
-12,708 Reduced 40.92%
18,350 $213,000
Q1 2021

May 17, 2021

BUY
$10.24 - $14.6 $5,632 - $8,030
550 Added 1.8%
31,058 $348,000
Q4 2020

Feb 12, 2021

BUY
$9.67 - $12.05 $295,012 - $367,621
30,508 New
30,508 $329,000

Others Institutions Holding IMTX

About Immatics N.V.


  • Ticker IMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,227,000
  • Market Cap $547M
  • Description
  • Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...
More about IMTX
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.